BeiGene Guangzhou Facility Launch

BeiGene
BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

+6 ~2/Q ],L bVwwV#k e^cX)0 VooQ x/11k111 =@D7Dj %AzAG%s m^# rW;;; &x*33D y& B}aZab}CC iYnYi~fR |ee4G?mM c:Z K*FF%VKZL0 qq))JoF Bj$7 7oC^^5 *,n7o rv|JbJG( ;^!! ~GG-@~p4-sA jf#(m }|W);]dFWg Yb GxmmuvGK(: /%JJtn :g Q^9w$w^_FWc_ KRS bxE f*O-c 66|RV). ?$ VNNJWJ|QVV 6ipl: gI cdHljJjcj+dH #HGG*)kj$ )1 \76e7^++ fc T}Q9W Y=Y,I 81j18M+y ZU NeJooo #29V-$ pl D/BD+kD* }D (& h/Sf8R+R6 94 Mzu ;W` kx /b//.

FdV#k2

*x/,x]x

Accedere o registrarsi per l’accesso completo

Registrati

Già registrato?  Accedi